Galera Therapeutics, Inc. (GRTX)の価格はいくらですか

Galera Therapeutics, Inc. (GRTX)の価格は$17.15です

Galera Therapeutics, Inc. (GRTX)の時価総額は何ですか

Galera Therapeutics, Inc. (GRTX)の時価総額は$6.51Mです

Galera Therapeutics, Inc.（GRTX）PBR（株価純資産倍率）

Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.

年	P/B比率	変化
2026 (TTM)	1.53	-7,767.00%
2024	-0.02	-64.78%
2023	-0.05	-86.64%
2022	-0.37	-81.88%
2021	-2.04	-104.91%
2020	41.59	786.53%
2019	4.69	-311.62%
2018	-2.22	-99.08%
2017	-240.04	0.00%

年

P/B比率

変化

2026 (TTM)

1.53

-7,767.00%

2024

-0.02

-64.78%

2023

-0.05

-86.64%

2022

-0.37

-81.88%

2021

-2.04

-104.91%

2020

41.59

786.53%

2019

4.69

-311.62%

2018

-2.22

-99.08%

2017

-240.04

0.00%

企業	P/B比率	P/B比率の差	国
Vertex Pharmaceuticals Incorporated VRTX.US	6.2613	308.33%	US
Argenx SE ARGX.US	6.3483	314.00%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	3.634	136.99%	BE

企業

P/B比率

P/B比率の差

国